Side-by-side · Research reference

Melanotan-IIvsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED9/43 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

Melanotan-II

Teriparatide

Primary target

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

—

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

Melanotan-II

Teriparatide

Loading phase

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

—

Maintenance

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

—

Frequency

Daily during loading; 1–2× per week maintenance

Once daily

Intermittent administration preserves anabolic effect.

Lower / starter dose

0.1 mg / day

Conservative starter — assess tolerability for nausea.

—

Evidence basis

Phase 1 + anecdotalDorr 1996

RCT / FDA-approved

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water; protect from light

—

Timing

Evening preferred (24h tan-development cycle)

Morning or evening (flexible)

Half-life

~1 hour plasma; effects on melanocytes persist days

—

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Route

—

Subcutaneous (thigh or abdomen)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

Melanotan-II

Teriparatide

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

Melanotan-II

Teriparatide

Nausea

Common, especially loading phase

Common, usually mild and transient

Flushing

Common transient

—

Spontaneous erection

Common in men — MC4R cross-effectDorr 1996

—

Increased mole / freckle pigmentation

Existing moles darken; new lesions possible

—

Melanoma risk

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

—

Appetite suppression

MC4R-mediated; mild

—

Pregnancy / OB

Contraindicated

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

Melanotan-II

Teriparatide

1. Reconstitution

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Injection site

SQ — abdomen. Rotate sites.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Timing

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Needle

29–31G insulin syringe.

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.